title: Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure.
abstract: High PTH levels have been reported in patients with chronic heart failure (CHF). Similarly, its levels increase with aging and are related to impaired survival in elderly adults. However, its relationship with neuroendocrine activation and endothelial dysfunction in CHF has not been previously studied. Seventy-three CHF males with New York Heart Association (NYHA) classes II and III and 20 control subjects aged ≥ 55 yr were recruited. PTH, 25-hydroxyvitamin D [25(OH)D], N-terminal pro-brain natriuretic peptide (NT-pro-BNP), adiponectin, and osteoprotegerin were measured. Endothelial function (brachial flow mediated dilation), echocardiography, physical performance, and quality of life were assessed, as well. CHF patients had markedly increased serum PTH (77 ± 33 vs 40 ± 11 pg/ml, p<0.0001), NT-pro-BNP [1809 (2742) vs 67 (74) pg/ml, p<0.0001], adiponectin (17 ± 9 vs 10 ± 2 μg/ml, p<0.0001), osteoprotegerin, whereas 25(OH)D levels were decreased compared to controls. Increased PTH is positively correlated with NTpro- BNP (r=0.399, p<0.0001), adiponectin (r=0.398, p<0.0001), and osteoprotegerin, whereas negatively with 25(OH)D in CHF patients. Additionally, increased serum PTH was associated with endothelial dysfunction, echocardiographic variables of heart failure progression, impaired physical performance, and deteriorated quality of life. In a multivariate linear regression analysis, increased serum PTH was independently associated with neuroendocrine activation (NT-pro-BNP, adiponectin) and endothelial dysfunction in elderly CHF men (R2=0.455). Additionally, demonstrated relations with other well-established variables of heart failure severity suggest the potential role of serum PTH in the pathogenesis and non-invasive monitoring of heart failure progression. Future studies are needed to evaluate the predictive value of serum PTH for clinical outcomes as well as beneficial potential of PTH suppression in CHF patients.
authors.affiliation: Cardiology Department, Clinical Medical Center Zvezdara, Belgrade, Serbia.
authors.forename: G
authors.initials: G
authors.lastname: Loncar
authors.forename: B
authors.initials: B
authors.lastname: Bozic
authors.forename: S
authors.initials: S
authors.lastname: Dimkovic
authors.forename: N
authors.initials: N
authors.lastname: Prodanovic
authors.forename: Z
authors.initials: Z
authors.lastname: Radojicic
authors.forename: V
authors.initials: V
authors.lastname: Cvorovic
authors.forename: B
authors.initials: B
authors.lastname: Putnikovic
authors.forename: V
authors.initials: V
authors.lastname: Popovic
mesh_terms: D052242:Adiponectin / Q000097:blood; D000368:Aged; D002908:Chronic Disease; D004730:Endothelium, Vascular / Q000503:physiopathology*; D006333:Heart Failure / Q000097:blood* / Q000503:physiopathology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D009490:Neurosecretory Systems / Q000502:physiology*; D053244:Osteoprotegerin / Q000097:blood; D010281:Parathyroid Hormone / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood; D012372:ROC Curve; D014652:Vascular Diseases / Q000097:blood / Q000503:physiopathology; D014807:Vitamin D / Q000097:blood
chemical_list: D052242:Adiponectin; D053244:Osteoprotegerin; D010281:Parathyroid Hormone; D010446:Peptide Fragments; C109794:pro-brain natriuretic peptide (1-76); D020097:Natriuretic Peptide, Brain; D014807:Vitamin D
references.citation: JAMA. 1993 Oct 13;270(14):1702-7
references.pmid: 8411500
references.citation: Heart. 1999 Dec;82 Suppl 4:IV8-IV10
references.pmid: 10574904
references.citation: N Engl J Med. 2002 Oct 31;347(18):1397-402
references.pmid: 12409541
references.citation: J Am Coll Cardiol. 2002 Jan 16;39(2):257-65
references.pmid: 11788217
references.citation: J Intern Med. 2009 Apr;265(4):488-95
references.pmid: 19019181
references.citation: Heart Fail Rev. 2006 Mar;11(1):45-55
references.pmid: 16819577
references.citation: Circ J. 2009 Jun;73(6):1012-3
references.pmid: 19465781
references.citation: Circulation. 1994 Dec;90(6):2772-9
references.pmid: 7994820
references.citation: Cardiovasc Res. 2009 Apr 1;82(1):77-83
references.pmid: 19168854
references.citation: J Clin Endocrinol Metab. 2008 Oct;93(10):3927-35
references.pmid: 18682515
references.citation: Circulation. 2005 Jan 25;111(3):310-4
references.pmid: 15655134
references.citation: Am Heart J. 1992 Oct;124(4):1017-25
references.pmid: 1529875
references.citation: Int J Cardiol. 2004 Apr;94(2-3):283-7
references.pmid: 15093994
references.citation: Cell. 2007 Aug 10;130(3):456-69
references.pmid: 17693256
references.citation: Circulation. 1997 Jul 15;96(2):526-34
references.pmid: 9244221
references.citation: N Engl J Med. 2008 May 15;358(20):2148-59
references.pmid: 18480207
references.citation: Hypertension. 2007 Jun;49(6):1392-8
references.pmid: 17470718
references.citation: Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
references.pmid: 12091180
references.citation: Clin Endocrinol (Oxf). 1999 Aug;51(2):217-21
references.pmid: 10468993
references.citation: Clin Med Res. 2007 Dec;5(4):238-43
references.pmid: 18367709
references.citation: Eur Heart J. 2003 Nov;24(22):2054-60
references.pmid: 14613742
references.citation: Clin Endocrinol (Oxf). 2008 Jul;69(1):29-35
references.pmid: 18208576
references.citation: J Am Coll Cardiol. 2004 Nov 16;44(10):1970-6
references.pmid: 15542278
references.citation: Clin Nephrol. 2004 Mar;61(3):177-84
references.pmid: 15077868
references.citation: Mol Cell Endocrinol. 2009 Oct 30;310(1-2):21-9
references.pmid: 19376193
references.citation: Diabetes Care. 2006 Jul;29(7):1664-6
references.pmid: 16801598
references.citation: Circulation. 2005 Feb 22;111(7):871-8
references.pmid: 15710759
references.citation: Circ J. 2007 May;71(5):623-30
references.pmid: 17456982
references.citation: Am J Med. 1997 Sep;103(3):197-207
references.pmid: 9316552
references.citation: Nephron. 1976;16(1):31-41
references.pmid: 1244564
references.citation: Radiology. 1982 Apr;143(1):29-36
references.pmid: 7063747
references.citation: Heart. 2009 Mar;95(5):395-8
references.pmid: 19001003
references.citation: Circulation. 1997 Sep 2;96(5):1416-23
references.pmid: 9315526
references.citation: J Am Coll Cardiol. 2003 Jan 1;41(1):105-12
references.pmid: 12570952
references.citation: Gerontology. 2009;55(4):405-10
references.pmid: 19571528
references.citation: Prog Cardiovasc Dis. 1994 Jan-Feb;36(4):309-42
references.pmid: 8284434
references.citation: Cardiology. 2008;111(1):51-6
references.pmid: 18239393
references.citation: Clin Chim Acta. 2006 Apr;366(1-2):27-36
references.pmid: 16313895
references.citation: Trends Endocrinol Metab. 2004 Mar;15(2):60-5
references.pmid: 15036251
references.citation: Med Hypotheses. 2005;64(5):1022-6
references.pmid: 15780504
references.citation: J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80
references.pmid: 17996563
references.citation: J Am Soc Echocardiogr. 2009 Mar;22(3):213-31; quiz 316-7
references.pmid: 19258174
references.citation: Eur Heart J. 2005 Jan;26(1):65-9
references.pmid: 15615801
references.citation: Heart. 2006 Oct;92(10):1420-4
references.pmid: 16621874